BUZZ-iBio rises as obesity drug gets first green light for human trial in Australia
Reuters04-08
BUZZ-iBio rises as obesity drug gets first green light for human trial in Australia
** Shares of biotech firm iBio IBIO.O rise 7% to $2.25 premarket
** Co says Australian regulators have cleared first human study of its experimental obesity drug IBIO-600
** Drug targets obesity and aims to preserve muscle while people lose weight - IBIO
** Says IBIO-600 is designed to be used alongside GLP-1 weight-loss drugs, which can cause muscle loss
** Adds early-stage study will test safety and how the drug behaves in overweight and obese adults
** Says animal studies showed gains in lean muscle and reductions in fat; drug could be dosed just a few times a year
** As of last close, IBIO up ~9% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments